Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis

International Journal of Molecular Medicine

Volumn 25, Issue 4, 2010, Pages 625-633

  Auci, Dominick L ^a   Mangano, Katia ^b   Destiche, Daniel ^a   White, Steven K ^a   Huang, Yujin ^a   Boyle, David ^c   Frincke, James ^a   Reading, Christopher L ^a   Nicoletti, Ferdinando ^b  

^a Eastgate Mall   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androstenetriol; Autoimmune diseases; Dehydroepiandrosterone; HE3286; Immunotherapy; Rheumatoid arthritis

Indexed keywords

17ALPHA ETHYNYL 5 ANDROSTENE 3BETA,7BETA,17BETA TRIOL; ANTIINFLAMMATORY AGENT; COLLAGEN ANTIBODY; DEXAMETHASONE; FREUND ADJUVANT; HE 3286; INTERLEUKIN 6; MYELOPEROXIDASE; TETRAMETHYLBENZIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; COXSACKIE VIRUS B3; DOSE RESPONSE; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART WEIGHT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NORMAL HUMAN; OPTICAL DENSITY; PAW EDEMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SPLEEN WEIGHT; THERAPY DELAY; TREATMENT DURATION; VIRUS MYOCARDITIS;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BODY WEIGHT; DEHYDROEPIANDROSTERONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENTEROVIRUS B, HUMAN; HUMANS; IMMUNIZATION; INTERLEUKIN-6; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MICE; MYOCARDITIS; ORGAN SIZE; PEROXIDASE; RATS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77749298292     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000385     Document Type: Article

References (48)

1. Kuek A, Hazleman BL and Ostor AJ: Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 83: 251-260, 2007.
2. Wislowska M and Jakubicz D: Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatol Int 27: 641-647, 2007.
3. Sandborn WJ and Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5: 119-133, 1999.
4. Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA and Villalona-Calero MA: Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 24: 1852-1859, 2006.
5. Kong JS, Teuber SS and Gershwin ME: Potential adverse events with biologic response modifiers. Autoimmun Rev 5: 471-485, 2006.
6. Schacke H, Docke WD and Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43, 2002.
7. Callen JP: Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 26: 6-14, 2007.
8. Berger JR, Houff S: Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 65: 367-377, 2009.
9. Turini ME and DuBois RN: Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53:35-57, 2002.
10. Serhan CN, Chiang N and Van Dyke TE: Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361, 2008.
11. Serhan CN: Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137, 2007.
12. Webb SJ, Geoghegan TE, Prough RA and Michael Miller KK: The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 38: 89-116, 2006.
13. Svec F and Porter JR: The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218: 174-191, 1998.
14. Auci DL, Ahlem C, Li M, Trauger R, Dowding C, Paillard F, Frincke J and Reading CL: The immunobiology and therapeutic potential of androstene hormones and their synthetic derivatives: novel anti-inflammatory and immune regulating steroid hormones. Mod Asp Immunobiol 3: 64-70, 2003.
15. Huppert FA, Van Niekerk JK and Herbert J: Dehydroepiandrosterone (DHEA) supplementation for cognition and well-being. Cochrane Database Syst Rev 2: CD000304, 2000.
16. Sirrs SM and Bebb RA: DHEA: panacea or snake oil? Can Fam Physician 45: 1723-1728, 1999.
17. Celec P and Starka L: Dehydroepiandrosterone - is the fountain of youth drying out? Physiol Res 52: 397-407, 2003.
18. Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M and Schwartz KE: Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 50: 2858-2868, 2004.
19. Leblanc M, Labrie C, Belanger A, Candas B and Labrie F: Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. J Clin Endocrinol Metab 88: 4293-4302, 2003.
20. Buster JE, Casson PR, Straughn AB, Dale D, Umstot ES, Chiamori N and Abraham GE: Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am J Obstet Gynecol 166: 1163-1170, 1992.
21. Fitzpatrick JL, Ripp SL, Smith NB, Pierce WM Jr and Prough RA: Metabolism of DHEA by cytochromes P450 in rat and human liver microsomal fractions. Arch Biochem Biophys 389: 278-287, 2001.
22. Marwah A, Marwah P and Lardy H: Ergosteroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. J Chromatogr B Biomed Sci Appl 767: 285-299, 2002.
23. Auci DL, Reading CL and Frincke JM: 7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases. Autoimmun Rev 8: 369-372, 2009.
24. Ahlem C, Auci D, Mangano K, Reading C, Frincke J, Stickney D and Nicoletti F: HE3286: a novel sythetic steroid as an oral treatment for autoimmune disease. Ann NY Acad Sci 1173: 781-790, 2009.
25. Offner H, Zamora A, Drought H, Matejuk A, Auci D, Morgan E, Vandenbark A and Reading C: A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J Neuroimmunol 130: 128-139, 2002.
26. Marcu AC, Kielar ND, Paccione KE, Barbee RW, Carter H, Ivatury RR, Diegelmann RF, Ward KR and Loria RM: Androstenetriol improves survival in a rodent model of traumatic shock. Resuscitation 71: 379-386, 2006.
27. Auci D, Kaler L, Subramanian S, Huang Y, Frincke J, Reading C and Offner H: A new orally bioavailable syntheic androstene inhibits collagen-induced arthritis in the mouse. Ann NY Acad Sci 1110: 630-640, 2007.
28. Offner H, Firestein GS, Boyle DL, Pieters R, Frincke JM, Garsd A, White SK, Reading CL and Auci DL: An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis. J Pharmacol Exp Ther 329: 1100-1109, 2009.
29. Hegen M, Keith JC Jr, Collins M and Nickerson-Nutter CL: Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 67: 1505-1515, 2008.
30. Conover WJ: Practical Nonparametric Statistics. 3rd edition, John Wiley & Sons Inc., New York, NY, pp271-364, 1999.
31. Casella G: Refining binomial confidence intervals. Can J Stat 14: 113-129, 1986.
32. Holmdahl R, Goldschmidt TJ, Kleinau S, Kvick C and Jonsson R: Arthritis induced in rats with adjuvant oil is a genetically restricted, alpha beta T-cell dependent autoimmune disease. Immunology 76: 197-202, 1992.
33. Kohashi O, Aihara K, Ozawa A, Kotani S and Azuma I: New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine-induced arthritis: clinical and histologic studies in athymic nude and euthymic rats. Lab Invest 47: 27-36, 1982.
34. Szekanecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Kenneth Haines G III, Kunkel SL, Burdick MD and Koch AE: Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum 43: 1266-1277, 2000.
35. Badolato R and Oppenheim JJ: Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 26: 526-538, 1996.
36. Haynes DR, Gadd SJ, Whitehouse MW, Mayrhofer G and Vernon-Roberts B: Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production. Inflamm Res 45: 159-165, 1996.
37. Magari K, Miyata S, Nishigaki F, Ohkubo Y and Mutoh S: Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm Res 53: 544-550, 2004.
38. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC and Gregory SA: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 97: 2672-2679, 1996.
39. Matsumoto A, Melian A, Shah A and Curtis SP: Etoricoxib versus naproxen in patients with rheumatoid arthritis: a prospective, randomized, comparator-controlled 121-week trial. Curr Med Res Opin 23: 2259-2268, 2007.
40. Nandakumar KS, Svensson L and Holmdahl R: Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. Am J Pathol 163: 1827-1837, 2003.
41. Lathe R: Steroid and sterol 7-hydroxylation: ancient pathways. Steroids 67: 967-977, 2002.
42. Liu D and Dillon JS: Dehydroepiandrosterone activates endothelial cell nitric oxide synthase by a specific plasma membrane receptor coupled to Galpha i2,3. J Biol Chem 277: 21379-21388, 2002.
43. Waterhouse RN, Chang RC, Atuehene N and Collier TL: In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand [18F]FPS. Synapse 61: 540-546, 2007.
44. Prossnitz ER, Sklar LA, Oprea TI and Arterburn JB: GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci 29: 116-123, 2008.
45. Zwar TD, van Driel IR and Gleeson PA: Guarding the immune system: Suppression of autoimmunity by CD4CD25 immuno-regulatory T cells. Immunol Cell Biol 84: 487-501, 2006.
46. Lohr J, Knoechel B, Wang JJ, Villarino AV and Abbas AK: Role of IL-17 and regulatory T lymphocytes in a systemic auto-immune disease. J Exp Med 203: 2785-2791, 2006.
47. + T cell regulatory functions. J Immunol 178: 271-279, 2007.
48. Marin V, Montero-Julian FA, Gres S, Boulay V, Bongrand P, Farnarier C and Kaplanski G: The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 167: 3435-3442, 2001.